How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.
Adult
Aged
Aged, 80 and over
Autopsy
Brain
/ pathology
Cognitive Dysfunction
/ physiopathology
Cohort Studies
Female
Humans
Male
Middle Aged
Ocular Motility Disorders
/ physiopathology
Parkinsonian Disorders
/ physiopathology
Postural Balance
Retrospective Studies
Sensation Disorders
/ physiopathology
Societies, Medical
Supranuclear Palsy, Progressive
/ classification
autopsy
diversity
phenotype
progressive supranuclear palsy
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
14
01
2019
revised:
10
02
2019
accepted:
18
02
2019
pubmed:
19
3
2019
medline:
26
6
2020
entrez:
19
3
2019
Statut:
ppublish
Résumé
The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them. We retrospectively collected standardized clinical data by chart review in a multicenter cohort of autopsy-confirmed patients with progressive supranuclear palsy, to classify them by diagnostic certainty level and predominance type and to identify multiple allocations. Comprehensive data were available from 195 patients. More than one diagnostic allocation occurred in 157 patients (80.5%). On average, 5.4 allocations were possible per patient. We developed four rules for Multiple Allocations eXtinction (MAX). They reduced the number of patients with multiple allocations to 22 (11.3%), and the allocations per patient to 1.1. The proposed MAX rules help to standardize the application of the Movement Disorder Society criteria for progressive supranuclear palsy. © 2019 International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them.
METHODS
We retrospectively collected standardized clinical data by chart review in a multicenter cohort of autopsy-confirmed patients with progressive supranuclear palsy, to classify them by diagnostic certainty level and predominance type and to identify multiple allocations.
RESULTS
Comprehensive data were available from 195 patients. More than one diagnostic allocation occurred in 157 patients (80.5%). On average, 5.4 allocations were possible per patient. We developed four rules for Multiple Allocations eXtinction (MAX). They reduced the number of patients with multiple allocations to 22 (11.3%), and the allocations per patient to 1.1.
CONCLUSIONS
The proposed MAX rules help to standardize the application of the Movement Disorder Society criteria for progressive supranuclear palsy. © 2019 International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 30884545
doi: 10.1002/mds.27666
pmc: PMC6699888
mid: NIHMS1026686
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1228-1232Subventions
Organisme : NIA NIH HHS
ID : P30 AG010124
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066507
Pays : United States
Organisme : Medical Research Council
ID : MR/L016397/1
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : K23 AG059891
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG066597
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS109260
Pays : United States
Informations de copyright
© 2019 International Parkinson and Movement Disorder Society.
Références
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Arch Neurol. 1964 Apr;10:333-59
pubmed: 14107684
Mov Disord. 2017 Jul;32(7):955-971
pubmed: 28500751
Neuropathol Appl Neurobiol. 2015 Feb;41(1):3-23
pubmed: 25495175
Mov Disord. 2014 Dec;29(14):1758-66
pubmed: 25370486
Mov Disord. 2017 Jul;32(7):995-1005
pubmed: 28500752
Mov Disord. 2019 Aug;34(8):1144-1153
pubmed: 30726566